JP2017523187A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523187A5 JP2017523187A5 JP2017504713A JP2017504713A JP2017523187A5 JP 2017523187 A5 JP2017523187 A5 JP 2017523187A5 JP 2017504713 A JP2017504713 A JP 2017504713A JP 2017504713 A JP2017504713 A JP 2017504713A JP 2017523187 A5 JP2017523187 A5 JP 2017523187A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- complex
- administered
- subject
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003812 Interleukin-15 Human genes 0.000 claims description 89
- 108090000172 Interleukin-15 Proteins 0.000 claims description 89
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 206010025327 Lymphopenia Diseases 0.000 claims description 13
- 231100001023 lymphopenia Toxicity 0.000 claims description 13
- 238000012423 maintenance Methods 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims description 5
- 102000056003 human IL15 Human genes 0.000 claims description 5
- 101001003140 Homo sapiens Interleukin-15 receptor subunit alpha Proteins 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 101150029707 ERBB2 gene Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 72
- 210000004027 cell Anatomy 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical group CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462030394P | 2014-07-29 | 2014-07-29 | |
| US62/030,394 | 2014-07-29 | ||
| PCT/US2015/042489 WO2016018920A1 (en) | 2014-07-29 | 2015-07-28 | Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523187A JP2017523187A (ja) | 2017-08-17 |
| JP2017523187A5 true JP2017523187A5 (enExample) | 2018-08-30 |
| JP6655061B2 JP6655061B2 (ja) | 2020-02-26 |
Family
ID=55218246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504713A Active JP6655061B2 (ja) | 2014-07-29 | 2015-07-28 | 状態を治療するためのｉｌ−１５およびｉｌ−１５ｒアルファヘテロ二量体用量増加レジメン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10335460B2 (enExample) |
| EP (1) | EP3174974B1 (enExample) |
| JP (1) | JP6655061B2 (enExample) |
| ES (1) | ES2811974T3 (enExample) |
| WO (1) | WO2016018920A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE037460T2 (hu) | 2005-12-02 | 2018-08-28 | Icahn School Med Mount Sinai | Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk |
| US20160015760A1 (en) | 2013-03-14 | 2016-01-21 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| CN112795594B (zh) | 2013-05-14 | 2025-09-19 | 得克萨斯州大学系统董事会 | 工程化嵌合抗原受体(car)t细胞的人应用 |
| JP6640726B2 (ja) | 2014-02-14 | 2020-02-05 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | キメラ抗原受容体及びその製造方法 |
| CA2940570A1 (en) | 2014-02-27 | 2015-09-03 | Viralytics Limited | Combination method for treatment of cancer |
| WO2017177063A1 (en) | 2016-04-06 | 2017-10-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of heterodimeric il-15 in adoptive cell transfer |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| WO2017201352A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| KR20220148306A (ko) | 2016-05-27 | 2022-11-04 | 알토 바이오사이언스 코포레이션 | Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명 |
| SI3464380T1 (sl) * | 2016-06-02 | 2025-03-31 | Immunocore Limited | Režim doziranja za gp100-specifični tcr - anti-cd3 scfv fuzijski protein |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| WO2018013855A2 (en) | 2016-07-14 | 2018-01-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Il-15/il-15 receptor alpha treatment regimens and use with therapeutic vaccines |
| WO2018132494A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| US20200237874A1 (en) * | 2017-01-20 | 2020-07-30 | Novartis Ag | Combination therapy for the treatment of cancer |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| CA3064375A1 (en) | 2017-05-25 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy |
| CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| RU2020128830A (ru) * | 2018-02-02 | 2022-03-03 | Новартис Аг | Комбинация агониста sting и il-15/il-15rа для лечения рака |
| JP7366056B2 (ja) | 2018-04-18 | 2023-10-20 | ゼンコア インコーポレイテッド | ＩＬ－１５／ＩＬ－１５ＲＡ Ｆｃ融合タンパク質およびＬＡＧ－３抗原結合ドメインを含む、ＬＡＧ－３を標的とするヘテロ二量体融合タンパク質 |
| JP7440102B2 (ja) | 2018-06-22 | 2024-02-28 | キュージーン インコーポレイテッド | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
| EP3810624A4 (en) | 2018-06-22 | 2022-07-06 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
| EP3837277A4 (en) | 2018-08-17 | 2022-05-11 | Icahn School of Medicine at Mount Sinai | RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION |
| US20210386788A1 (en) * | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2020132646A1 (en) | 2018-12-20 | 2020-06-25 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
| CA3126153A1 (en) * | 2019-01-11 | 2020-07-16 | Memorial Sloan Kettering Cancer Center | Multimerization of il-15/il-15r-alpha-fc complexes to enhance immunotherapy |
| AU2020345943A1 (en) | 2019-09-10 | 2022-03-31 | Obsidian Therapeutics, Inc. | CA2-IL15 fusion proteins for tunable regulation |
| CN115151279A (zh) * | 2019-12-13 | 2022-10-04 | 科优基因公司 | 基于细胞因子的可生物活化药物及其使用方法 |
| CN115443127A (zh) * | 2020-04-22 | 2022-12-06 | 诺华股份有限公司 | 异源二聚体人白介素-15(hetil-15)的药物组合物和药物产品 |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| WO2024040132A2 (en) | 2022-08-16 | 2024-02-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Synergistic interactions for improved cancer treatment |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| WO2025085672A1 (en) | 2023-10-17 | 2025-04-24 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
| WO2025184249A1 (en) * | 2024-02-28 | 2025-09-04 | Emory University | Cytokine therapies for managing hiv and other viral infections |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2444713A1 (fr) | 1978-12-18 | 1980-07-18 | Pasteur Institut | Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| DE4135070C1 (enExample) | 1991-10-24 | 1993-05-19 | Institut Fuer Rundfunktechnik Gmbh, 8000 Muenchen, De | |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5591630A (en) | 1994-05-06 | 1997-01-07 | Immunex Corporation | Monoclonal antibodies that bind interleukin-15 receptors |
| US6569681B1 (en) | 2000-03-14 | 2003-05-27 | Transkaryotic Therapies, Inc. | Methods of improving homologous recombination |
| WO2002098370A2 (en) | 2001-03-02 | 2002-12-12 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| EP1718670B1 (en) | 2004-02-27 | 2011-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity |
| AU2006262711B2 (en) * | 2005-05-17 | 2013-01-31 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| US8021668B2 (en) | 2005-12-12 | 2011-09-20 | Immune Disease Institute, Inc. | Integrin alpha L I domain mutants with increased binding affinity |
| CA2636111C (en) | 2006-01-13 | 2018-04-03 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells |
| EP2160401B1 (en) | 2007-05-11 | 2014-09-24 | Altor BioScience Corporation | Fusion molecules and il-15 variants |
| WO2010020047A1 (en) | 2008-08-22 | 2010-02-25 | Magna Seating Inc. | Disc recliner with reduced backlash |
| US8871191B2 (en) | 2009-08-14 | 2014-10-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of IL-15 preparations to treat lymphopenia |
| EP3851459B1 (en) | 2010-09-21 | 2024-05-01 | Altor BioScience, LLC | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| JP6359019B2 (ja) * | 2012-10-24 | 2018-07-18 | ノバルティス アーゲー | ＩＬ−１５Ｒα型、ＩＬ−１５Ｒα型を発現する細胞、ならびにＩＬ−１５ＲαおよびＩＬ−１５／ＩＬ−１５Ｒα複合体の治療上の使用 |
-
2015
- 2015-07-28 EP EP15828027.1A patent/EP3174974B1/en active Active
- 2015-07-28 US US15/328,882 patent/US10335460B2/en active Active
- 2015-07-28 JP JP2017504713A patent/JP6655061B2/ja active Active
- 2015-07-28 WO PCT/US2015/042489 patent/WO2016018920A1/en not_active Ceased
- 2015-07-28 ES ES15828027T patent/ES2811974T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523187A5 (enExample) | ||
| Kozuch et al. | Treatment of inflammatory bowel disease: a review of medical therapy | |
| JP5320301B2 (ja) | 感染症の処置のためのｉｌ−２３アンタゴニストの使用 | |
| JP2014515763A5 (enExample) | ||
| Stallmach et al. | An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn’s disease and experimental colitis in vivo | |
| RU2676333C2 (ru) | Способы снижения частоты приступов астмы с применением бенрализумаба | |
| Martin | Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing–remitting multiple sclerosis | |
| Dharmani et al. | Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key | |
| JP2016527286A5 (enExample) | ||
| JP2013508392A5 (enExample) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| US20080008716A1 (en) | Combined Pharmaceutical Composition Comprising an Anti-4-1BB Monoclonal Antibody and Chemotherapeutic Anti-Cancer Agent for Preventing and Treating Cancer Disease | |
| JP2013543501A5 (enExample) | ||
| JP2022160685A5 (enExample) | ||
| JP2019517549A5 (enExample) | ||
| JP2014500278A5 (enExample) | ||
| JP2022188083A5 (enExample) | ||
| JP2015500822A5 (enExample) | ||
| Kochetkova et al. | Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27 | |
| US20200377596A1 (en) | Dosing of bispecific t cell engager | |
| JP2019519584A5 (enExample) | ||
| Danese et al. | Biological Therapies for Inflammatory Bowel Disease: Research DrivesClinics | |
| JP2021504404A5 (enExample) | ||
| Argollo et al. | Interleukin-23 blockers: born to be first-line biologic agents in inflammatory bowel disease? | |
| JPWO2021123902A5 (enExample) |